company background image
FRLN

Freeline Therapeutics Holdings NasdaqGS:FRLN Stock Report

Last Price

US$0.64

Market Cap

US$41.6m

7D

-0.3%

1Y

-72.4%

Updated

29 Nov, 2022

Data

Company Financials +
FRLN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

FRLN Stock Overview

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases.

Freeline Therapeutics Holdings plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Freeline Therapeutics Holdings
Historical stock prices
Current Share PriceUS$0.64
52 Week HighUS$2.64
52 Week LowUS$0.60
Beta0.20
1 Month Change-15.79%
3 Month Change-24.66%
1 Year Change-72.41%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.44%

Recent News & Updates

We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Aug 30
We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Freeline gains as NEJM publishes long-term data for hemophilia therapy

Jul 21

Recent updates

We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Aug 30
We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

May 05
Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Jan 13
Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

Sep 30
Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

Jun 03
Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Feb 18
What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Shareholder Returns

FRLNUS BiotechsUS Market
7D-0.3%0.2%0.3%
1Y-72.4%-16.1%-20.5%

Return vs Industry: FRLN underperformed the US Biotechs industry which returned -16.1% over the past year.

Return vs Market: FRLN underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is FRLN's price volatile compared to industry and market?
FRLN volatility
FRLN Average Weekly Movement10.4%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: FRLN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: FRLN's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015235Michael Parinihttps://www.freeline.life

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company’s products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy.

Freeline Therapeutics Holdings plc Fundamentals Summary

How do Freeline Therapeutics Holdings's earnings and revenue compare to its market cap?
FRLN fundamental statistics
Market CapUS$41.58m
Earnings (TTM)-US$100.67m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FRLN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$100.67m
Earnings-US$100.67m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.55
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did FRLN perform over the long term?

See historical performance and comparison